The Executive Yuan announced on June 25 and August 2 the amendment of controlled drugs scheduling and items. Hexahydrocannabihexol(HHCH) and Hexahydrocannabinol(HHC) were added as Schedule 2 controlled drugs; Etomidate was added as Schedule 4 controlled drug; 3-Oxo-2-phenylbutanamide(α-Phenylacetoacetamide、APAA), N-Methylpseudoephedrine, MDP2P methyl glycidic acid(PMK glycidic acid、3,4-MDP-2-P methyl glycidic acid), and 3,4-methylenedioxyphenyl-2-propanone(MDP2P) were added as Schedule 4 controlled drug materials. Also the Chinese name of “Parahexyl” listed on item 125 of schedule 2 controlled drugs was amended.

The above mentioned three emerging substances of abuse: HHCH, HHC and Etomidate, only Etomidate has anesthetic effect, the other two has no medicinal use; because these emerging substances of abuse may have entered the market and been abused, thus cause harm to our society, as these substances have scientific usage thus enlisted as controlled drugs. Considering scientific use and demands of testing and identification, the four Category 4 narcotics materials were added as schedule 4 controlled drug materials.

From the effective date of the announcement, for institutions and industry that has kept, need to import, export, manufacture, sell, purchase the aforementioned controlled drug items, should apply for controlled drugs registration certificate beforehand, and kept records of drug increase, decrease on a daily bases at business premises, periodical reports shall be made to the local competent health authority and the FDA. Medicinal or educational researchers who have needs of use of the said items, shall apply to FDA before use, and commence dispense the drugs after permission is granted. Whoever when handle the import export, manufacture, selling, purchase and use of the said drugs, should follow the controlled drugs act regulations to avoid violation and punishment.